SNN

Smith & Nephew PLC

Add to Watchlist

Advanced Chart

36.290

+0.09(0.249%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

36.640

Open

36.640

VWAP

36.47

Vol

304.86K

Mkt Cap

15.80B

Low

36.290

Amount

11.12M

EV/EBITDA(TTM)

12.17

Total Shares

873.13M

18.70B

EV/OCF(TTM)

16.33

P/S(TTM)

2.70

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2029Q4

FY2029Q3

FY2029Q2

1.47B

+4.19%

1.67B

+6.45%

1.52B

+7.55%

Estimates Revision

The market is revising Upward the revenue expectations for Smith & Nephew plc (SNN) for FY2025, with the revenue forecasts being adjusted by 0.49% over the past three months. During the same period, the stock price has changed by 24.71%.

Revenue Estimates for FY2025

Revise Upward

+0.49%

In Past 3 Month

Stock Price

Go Up

+24.71%

In Past 3 Month

2 Analyst Rating

-11.46% Downside

Wall Street analysts forecast SNN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNN is 32.13 USD with a low forecast of 29.26 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

-11.46% Downside

Current: 36.290

Low

29.26

Averages

32.13

High

35.00

-11.46% Downside

Current: 36.290

Low

29.26

Averages

32.13

High

35.00

Berenberg

Sam England

Hold

maintain

2025-08-11

Reason

Berenberg

Sam England

Price Target

2025-08-11

maintain

Hold

Reason

Berenberg analyst Sam England raised the firm's price target on Smith & Nephew to 1,300 GBp from 1,100 GBp and keeps a Hold rating on the shares.

JPMorgan

NULL

Overweight

upgrade

2025-07-09

Reason

JPMorgan

Price Target

2025-07-09

upgrade

NULL

Overweight

Reason

JPMorgan raised the firm's price target on Smith & Nephew to 1,357 GBp from 1,317 GBp and keeps an Overweight rating on the shares.

Citi

Buy

maintain

2025-06-05

Reason

Citi

Price Target

2025-06-05

maintain

Buy

Reason

Citi raised the firm's price target on Smith & Nephew to 1,450 GBp from 1,425 GBp and keeps a Buy rating on the shares.

HSBC

Buy

Hold

downgrade

2025-04-25

Reason

HSBC

Price Target

2025-04-25

downgrade

Buy

Hold

Reason

HSBC downgraded Smith & Nephew to Hold from Buy with a price target of 1,070 GBp, down from 1,160 GBp. The firm adjusted ratings in medical technology and life sciences are quantifying the risk/reward using stagflation, weak macro environment, and recovery scenario analyses. The market is debating whether the recent multiples correction is an opportunity to buy, or if it is the start of a potential recession, the analyst tells investors in a research note. HSBC's analysis of historical sector multiples reveals that the multiples compression might have an additional 20%-25% downside in a stagflation scenario. "We are far from the point where one can argue that these stocks are pricing in a recession," contends HSBC.

Canaccord Genuity

Caitlin Cronin

Hold

Maintains

$27

2025-03-17

Reason

Canaccord Genuity

Caitlin Cronin

Price Target

$27

2025-03-17

Maintains

Hold

Reason

UBS

Graham Doyle

Strong Buy

Hold

Downgrades

n/a

2025-03-12

Reason

UBS

Graham Doyle

Price Target

n/a

2025-03-12

Downgrades

Strong Buy

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Smith & Nephew PLC (SNN.N) is 18.30, compared to its 5-year average forward P/E of 17.87. For a more detailed relative valuation and DCF analysis to assess Smith & Nephew PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

17.87

Current PE

18.30

Overvalued PE

21.43

Undervalued PE

14.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

11.22

Current EV/EBITDA

11.11

Overvalued EV/EBITDA

13.18

Undervalued EV/EBITDA

9.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

2.45

Current PS

2.52

Overvalued PS

3.02

Undervalued PS

1.88

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 225.78% over the last quarter.

Sold

0-3

Months

5.5M

Volume

3-6

Months

1.7M

Volume

6-9

Months

2.9M

Volume

0-12

Months

6.1M

Volume

Bought

0-3

225.5K

Volume

Months

3-6

3.8M

Volume

Months

6-9

7.2M

Volume

Months

0-12

22.1M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

8.0K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

SNN News & Events

Events Timeline

2025-07-07 (ET)

2025-07-07

10:01:37

Smith & Nephew announces release of Q-FIX Knotless All-Suture Anchor

2025-06-24 (ET)

2025-06-24

10:05:03

Smith & Nephew announces launch of TRIGEN MAX Tibia Nailing System

2025-06-23 (ET)

2025-06-23

08:03:52

Smith & Nephew names Ajay Dhankhar chief corporate development, strategy officer

News

9.5

08-05Benzinga

Sterling Infrastructure Posts Better-Than-Expected Earnings, Joins Lemonade, DigitalOcean Holdings, Lattice Semiconductor And Other Big Stocks Moving Higher On Tuesday

3.0

08-05Benzinga

Top 2 Health Care Stocks You May Want To Dump In Q3

9.5

08-05Benzinga

Why Palantir Technologies Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket